Interferal ® is used intramuscularly, in the focus or under the lesion, subconjunctivally. Immediately before use, the contents of the ampoule are dissolved in water for injection. The dissolution time of the contents of the ampoule is no more than 3 minutes. The drug solution should be transparent, without foreign inclusions. The diluted drug is not subject to storage.
Intramuscular injection. In acute hepatitis B Interferal® is administered 1 million ME 2 times a day for 5-6 days, then the dose is reduced to 1 million ME in a day and injected for another 5 days. If necessary (after control biochemical blood tests), the treatment course can be continued for 1 million ME 2 times a week for 2 weeks. The course dose is from 15 to 21 million ME.
In acute prolonged and chronic active hepatitis B, with the exception of delta infection and without evidence of cirrhosis of the liver, Interferal® is administered 1 million ME 2 times a week for 1-2 months. If there is no effect, treatment should be extended to 3-6 months or after 2-3 months of treatment, 2-3 similar courses should be performed at intervals of 1-6 months.
With chronic active hepatitis without signs of liver cirrhosis, the drug is injected at 500,000 to 1 million ME in a day 2 times a week for 1 month. Repeated course of treatment after 1-6 months.
With chronic active hepatitis B and D with signs of cirrhosis of the liver for 250-500 thousand ME in a day 2 times a week for 1 month. When there are signs of decompensation, similar repeated courses are conducted with an interval of at least 2 months.
In chronic viral hepatitis C, monotherapy with Interferal ® is recommended for subcutaneously 3 million ME 1 time per day every other day for 24 weeks or combined therapy with ribavirin.In case of recurrence of the disease after the course of monotherapy with interferon, the repeated course should be performed in combination with ribavirin for at least 6 months. After the control virological studies of blood in patients with HCV of the 1 st genotype and a high content of the virus RNA, which do not detect RNA of hepatitis C virus (RNA) by the end of the first 6 months of therapy in serum HCV), treatment continues for another 6 months.
In case of cancer of the kidney, Interferal® is used for 3 million ME daily for 10 days. Repeated courses of treatment (3-9 or more) are carried out at intervals of 3 weeks. The total amount of the drug is from 120 million ME up to 300 million ME and more.
With hairy cell leukemia, Interferal is administered daily 3 to 6 million ME within 2 months. After the normalization of the hemogram, the daily dose of the drug is reduced to 1-2 million ME. Then, supportive therapy for 3 million ME 2 times a week for 6-7 weeks. The total amount of the drug is from 420 to 600 million ME and more.
In acute lymphoblastic leukemia in children in the remission period after the end of inductive chemotherapy (for 4-5 months of remission), 1 million ME 1 time a week for 6 months, then 1 every 2 weeks for 24 months. Simultaneously, supportive chemotherapy is performed.
With chronic myelogenous leukemia for 3 million ME daily or 6 million ME in one day.Term of treatment from 10 weeks to 6 months.
With histocytosis-X, 3 million ME daily for 1 month. Repeated courses with 1 -2-month intervals for 1 -3 years.
With subleukemic myelosis and essential thrombocytopenia for correction of hyperthrombocytosis by 1 million ME daily or after 1 day for 20 days.
With malignant lymphomas and Kaposi's sarcoma, Interferal® is administered 3 million ME in a day daily for 10 days in combination with cytostatics (prospidin, cyclophosphamide) and glucocorticosteroids. In the tumor stage of fungal mycosis and reticulosarcomatosis, it is advisable to alternate intramuscular injection of Interferal ® preparation to 3 million ME and intrafocal for 2 million ME within 10 days.
In patients with erythrodermic stage of fungal mycosis, when the temperature rises above 39 ° C and in case of aggravation of the process, the drug administration should be discontinued. In case of insufficient therapeutic effect, after 10-14 days a second course of treatment is prescribed. After achieving a clinical effect, a maintenance therapy of 3 million ME 1 time per week for 6-7 weeks.
With respiratory papillomatosis of the larynx, the drug is injected at 100-150 thousand ME per 1 kg of body weight daily for 45-50 days, then at the same dosage 3 times a week for 1 month. The second and third courses are conducted at intervals of 2-6 months.
With multiple sclerosis, Interferal® is prescribed 1 million ME: with pyramidal syndrome 3 times a day, with cerebellar syndrome 1-2 times a day for 10 days, followed by the introduction of 1 million ME Once a week for 5-6 months. The total amount of the drug is from 50 to 60 million ME.
In persons with a high pyrogenic reaction (39 ° C and above), the simultaneous use of non-steroidal anti-inflammatory drugs is recommended for the administration of Interferal®.
Perifocal administration. In basal cell and squamous cell carcinoma, Interferal ® keratoacanthoma is administered under the lesion of 1 million ME 1 time per day daily for 10 days. In the case of pronounced local inflammatory reactions, the injection under the lesion is carried out after 1-2 days. At the end of the course, if necessary, conduct a cryodestruction.
Subconjunctival administration. With stromal keratitis and keratoiridocyclitis, subconjunctival injections of Interferal® at a dose of 60,000 ME in a volume of 0.5 ml daily or every other day, depending on the severity of the process. Injections are performed under local anesthesia with a 0.5% solution of dicain. The course of treatment for 15 to 25 injections.